TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Città di Torino
AO Cuneo
ASL Asti
ASL Cuneo 2
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Tipo pubblicazione
Multicenter Study
Autori/Collaboratori (30)Vedi tutti...
Filippi R
Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, Orbassano, Italy; Division of Medical Oncology 1, Department of Oncology, Città della Salute e della Scienza Hospital, Turin, Italy.
Brusa F
Department of Medical Oncology, Cardinal Massaia Hospital, Asti, Italy.
Prati V
Department of Medical Oncology, Michele e Pietro Ferrero Hospital, Verduno-Azienda Sanitaria Locale CN2, Alba-Bra, Cuneo, Italy.
et alii...
Abstract
BACKGROUND: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) dramatically changed. PEACE-1 and ARASENS trials established triplet therapy efficacy. Identifying prognostic factors supporting treatment choice is pivotal. METHODS: TEAM is an observational, retrospective study to evaluate prognostic role of variables in mHSPC patients receiving upfront docetaxel in 11 Italian centers. Outcome measures were progression-free survival (PFS) and overall-survival (OS). RESULTS: From September 2014 to December 2020, 147 patients were included. Median PFS and OS were 11.6 and 37.4 months. At univariate analysis, PFS-related variables were Gleason Score (GS) (P = .001), opioid use (P = .004), bone metastases number (P < .001), baseline PSA (P = .006), Hb (P < .001), ALP (P < .001) and LDH (P = .002), time between ADT and docetaxel start (P = .018), 3-month PSA (P < .001) and ALP (P < .001), and number of docetaxel cycles (P < .001). OS-related variables were PSA at diagnosis (P = .024), primary tumor treatment (P = .022), baseline pain (P = .015), opioid use (P < .001), bone metastases number (P < . 001), baseline Hb (P < .001), ALP (P < .001) and LDH (P = .001), NLR ratio (P = .039), 3-month PSA (P < .001) and ALP (P < .001) and docetaxel cycles number (P < .001). At multivariate analysis, independent prognostic variables were GS, opioid use, baseline LDH and time between ADT and docetaxel initiation for PFS, and baseline Hb and LDH for OS. CONCLUSION: Patients receiving upfront docetaxel with high GS, high disease burden, pain or opioid use, baseline unfavorable laboratory values had worse outcomes. Patients had greater docetaxel benefit when initiated early after ADT start. These parameters could be taken into account when selecting candidates for triplet therapy.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 37798164
DOI : 10.1016/j.clgc.2023.08.006
Keywords
Prognostic factors; Triplet therapy; Metastatic hormone-sensitive prostate cancer; Male; Humans; Docetaxel; Retrospective Studies; Prostate-Specific Antigen; Analgesics, Opioid/therapeutic use; Androgen Antagonists/therapeutic use; Treatment Outcome; Prostatic Neoplasms/pathology; Docetaxel; Hormones; Pain/etiology; Antineoplastic Combined Chemotherapy Protocols;